Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 10/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 4/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554684 | 0.92 | SLC16A3 (0.64) | SLC16A3MEN1MAPK1KMT2APLK1 | |
| SCHEMBL3558368 | 0.84 | SLC16A3 (0.60) | SLC16A3L3MBTL1PLK1PLK3 | |
| SCHEMBL3552416 | 0.83 | SLC16A3 (0.62) | SLC16A3L3MBTL1ALDH1A1KMT2APLK1 | |
| SCHEMBL3554752 | 0.83 | SLC16A3 (0.68) | SLC16A3L3MBTL1PLK1PLK3 | |
| SCHEMBL3559356 | 0.81 | SLC16A3 (0.60) | SLC16A3ALDH1A1MAPT | |
| SCHEMBL3561877 | 0.81 | SLC16A3 (0.65) | SLC16A3L3MBTL1PLK1PLK3 | |
| SCHEMBL3561881 | 0.81 | SLC16A3 (0.65) | SLC16A3L3MBTL1PLK1PLK3 | |
| SCHEMBL3553748 | 0.78 | SLC16A3 (0.65) | SLC16A3MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL3555542 | 0.78 | SLC16A3 (0.68) | SLC16A3ALDH1A1KMT2ASMN1; SMN2PLK1 | |
| SCHEMBL7632110 | 0.78 | PLK1 (0.56) | L3MBTL1ALDH1A1PLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885L3MBTL1 2080/4885MEN1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.